VisionBlue Ad, Website Omit Risk Information, FDA Warning Letter Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Dutch Ophthalmic has posted a disclaimer on its website and plans to run corrective ads in response to the citation for failing to include risk information in marketing materials for the staining agent. WLF's "DDMAC Watch" is challenging FDA's warning letter on VisionBlue.
You may also be interested in...
Washington Legal Foundation To Keep Eye On FDA’s Ad Division With “DDMAC Watch”
WLF will consider litigation against FDA in the case of inappropriate trends in the ad division’s warning and untitled letters. The program’s “rapid response” component will send responses to DDMAC letters specifically addressing “legally deficient or ill-advised” citations.
FDA Clears VisionBlue For Use In Ophthalmic Surgery
Dutch Ophthalmic’s VisionBlue is the first product approved for staining the anterior lens capsule during cataract surgery, FDA says. Safety and effectiveness of trypan blue ophthalmic solution were established in pediatric patients; no differences have been observed between elderly and younger patients.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.